Centers | ||
TEST | Edinburgh Drug Discovery | FDA Oncology Center of Excellence Project Catalyst |
info here |
Based within the world-leading University of Edinburgh Medical School, Edinburgh Drug Discovery has a track record in successfully translating drug discovery projects from target identification through to clinical evaluation. Key areas of... |
Providing a regulatory platform to connect scientific knowledge, creative insight, and medical professionals to foster early-stage product innovation |
Partnerships |
Events |
Jobs |
Vanderbilt and Astra Zeneca to Develop New Drugs to Treat Psychosis and Other Brain DisordersUnder a new research collaboration agreement, Vanderbilt Center for Neuroscience Drug Discovery (VCNDD) and Astra Zeneca will work together to develop compounds that act on M4 muscarinic acetylcholine receptor. The agreement entails research... View all Cerecor Partners with Johns Hopkins Brain Science Institute to Treat SchizophreniaCerecor a Baltimore based company has taken an option with Johns Hopkins University to license D-Amino Acid Oxidase inhibitors (DAAO) to treat Schizophrenia. The DAAO inhibitor molecules are currently being developed by researchers at the Johns... View all Johns Hopkins BSi Licenses GCPII Assets from EisaiJohns Hopkins Brain Science Institute ("BSi") has taken a non-exclusive license from Eisai to develop new compounds related to Glutamate Carboxypeptidase II (GCP-II) technology. The new compounds developed under this license will be targeted... View all |
No EVENTS for listing |
No Job Posts |


